A Feasibility Study of a Fecal Incontinence Management System for Medical Use
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is at least 18 years of age
- The subject has fecal incontinence
Exclusion Criteria:
- The subject is pregnant and/or breastfeeding
- The subject has perianal fistulas and/or hemorrhoids
- It's estimated that the subject's perianal skin makes it inappropriate for subject to participate in the study (i.e. in case of damaged skin, very sweaty skin or very sinuous and folded skin)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fecal Incontinence management system
Fecal Incontinence Management System is based on the same principle as fecal pouches.
A barrier around anus to ensure adhesion and prevent leakage.
|
The device is intended to remedy fecal incontinence.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Primary Outcome Measure is Device Wear Time (Time From the Device is Applied Until it is Removed)
Time Frame: 5 days
|
5 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Is the Barrier Size and Shape Satisfactory
Time Frame: Subjects were followed for the duration of the study, an average of 23 hours
|
Percentage of subjects who answered yes to the question: is the barrier size and shape satisfactory
|
Subjects were followed for the duration of the study, an average of 23 hours
|
|
Assessment of Skin 0-2 Inches From the Edge of the Anus
Time Frame: Subjects were evaluated before and after test
|
Skin condition scale: 1 = Normal skin without redness, 2 = Normal redness and intact skin, 3 = Abnormal redness but intact skin, 4 = Red and spotted but intact skin, 5 = Red and broken skin, 6 = Broken and bleeding skin Best skin condition score is 1, and worst skin condition score is 6.
|
Subjects were evaluated before and after test
|
|
What is Your Assessment of the Ease of Correct Application of the Anal Adhesive?
Time Frame: After application of product
|
After application of product
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Thais Benjamin N. Christensen, M.Sc. (BME), Coloplast A/S
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DK172OS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.